Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Table 4 5-Year Risk of Hepatocellular Carcinoma in T2DM Patients with Cirrhosis

	Kaplan Meier Estimates
5-Year Absence of Hepatocellular Carcinoma (%)	After Propensity Score Matching
5-Year Absence of Hepatocellular Carcinoma (%)	Metformin	Metformin + SGLT2-i	P	HR (95%CI)
All	93.75	98.61	0.017	0.43 (0.21–0.88)
Subgroup ^a				-
Men	86.91	99.64	0.051	0.24 (0.05–1.14)
Women	85.02	97.72	0.106	0.52 (0.23–1.16)
White	92.71	98.18	0.029	0.44 (0.21–0.93)
Non-White	96.87	99.49	0.100	0.2 (0.02–1.69)
Hispanic	95.54	99.17	0.385	0.38 (0.04–3.7)
Non-Hispanic	93.32	98.18	0.037	0.46 (0.22–0.97)
Age 39–59	95.21	99.44	0.134	0.31 (0.06–1.56)
Age 60–80	97.18	98.64	0.051	0.4 (0.16–1.03)
MASH ^b	93.61	98.72	0.120	0.08 (0.01–0.62)

^a Type 2 diabetes mellitus (T2DM) patients with cirrhosis treated with metformin and sodium glucose cotransporter-2 inhibitors (SGLT2-I) were further divided into demographic subgroups and propensity score matched to the Metformin group by sex, race, ethnicity, and age groups
^b T2DM patients with non-alcoholic steatohepatitis (MASH) Cirrhosis treated with metformin and SGLT2-I were propensity score matched to T2DM patients with MASH cirrhosis on metformin (n = 2,820)
K-M probabilities values are percent free of death. P values indicate P Log-rank Test
CI, Confidence Interval; HR, Hazard Ratio; K-M, Kaplan Meier

ISSN: 1471-230X